General Meeting of Shareholders

Unlike many Japanese companies, which have fiscal years ending in March, Chugai’s fiscal year ends in December. As a result, we can avoid holding our general meeting of shareholders on the same day as other companies.

Notice of convocation for the general meeting of shareholders are normally sent out more than four weeks prior to the meeting date.

The 113th annual general meeting of shareholders was held on March 28, 2024. After the presentation of the business report, shareholders deliberated on agenda items concerning appropriation of surplus, partial amendment to the articles of incorporation, election of directors, election of audit & supervisory board members, and revision of remuneration limit of audit & supervisory board members. All agenda items were approved and passed by a majority.

IR Activities

In 2023, we held meetings on financial results and new products, as well as R&D and sustainability, addressing areas of high need. We also held an IR Day, which we continue to hold in a format in which institutional investors and securities analysts can engage in direct dialogue with the Company’s CEO and other members of management in a setting with a small number of people. Dr. Mariko Y Momoi also participated in discussion this time, due to high demand for direct dialogue with independent outside directors. Furthermore, in addition to conducting online company briefings for individual investors focusing on themes such as the Company’s strengths of antibody engineering technologies and DX, we conducted a tour of Chugai Life Science Park Yokohama, which is a new research center that started full-scale operations in April 2023, for institutional investors and securities analysts.

Due to the introduction of the Principles for Responsible Institutional Investors (Japan’s Stewardship Code) and Japan’s Corporate Governance Code, greater dialogue between companies and shareholders is required. Chugai has proactively established forums for ongoing discussions between investors and the management team to ensure a fuller exchange of opinions. We will continue measures to enhance face-to-face IR with management.